• Sneha S Jain, Qi Liu, Jayant Raikhelkar, Justin Fried, Pierre Elias, Timothy J Poterucha, Ersilia M DeFilippis, Hannah Rosenblum, Elizabeth Y Wang, Bjorn Redfors, Kevin Clerkin, Jan M Griffin, Elaine Y Wan, Marwah Abdalla, Natalie A Bello, Rebecca T Hahn, Daichi Shimbo, Shepard D Weiner, Ajay J Kirtane, Susheel K Kodali, Daniel Burkhoff, LeRoy E Rabbani, Allan Schwartz, Martin B Leon, Shunichi Homma, Marco R Di Tullio, Gabriel Sayer, Nir Uriel, and D Edmund Anstey.
• Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, New York.
• J Am Soc Echocardiogr. 2020 Oct 1; 33 (10): 1278-1284.

BackgroundDespite growing evidence of cardiovascular complications associated with coronavirus disease 2019 (COVID-19), there are few data regarding the performance of transthoracic echocardiography (TTE) and the spectrum of echocardiographic findings in this disease.MethodsA retrospective analysis was performed among adult patients admitted to a quaternary care center in New York City between March 1 and April 3, 2020. Patients were included if they underwent TTE during the hospitalization after a known positive diagnosis for COVID-19. Demographic and clinical data were obtained using chart abstraction from the electronic medical record.ResultsOf 749 patients, 72 (9.6%) underwent TTE following positive results on severe acute respiratory syndrome coronavirus-2 polymerase chain reaction testing. The most common clinical indications for TTE were concern for a major acute cardiovascular event (45.8%) and hemodynamic instability (29.2%). Although most patients had preserved biventricular function, 34.7% were found to have left ventricular ejection fractions ≤ 50%, and 13.9% had at least moderately reduced right ventricular function. Four patients had wall motion abnormalities suggestive of stress-induced cardiomyopathy. Using Spearman rank correlation, there was an inverse relationship between high-sensitivity troponin T and left ventricular ejection fraction (ρ = -0.34, P = .006). Among 20 patients with prior echocardiograms, only two (10%) had new reductions in LVEF of >10%. Clinical management was changed in eight individuals (24.2%) in whom TTE was ordered for concern for acute major cardiovascular events and three (14.3%) in whom TTE was ordered for hemodynamic evaluation.ConclusionsThis study describes the clinical indications for use and diagnostic performance of TTE, as well as findings seen on TTE, in hospitalized patients with COVID-19. In appropriately selected patients, TTE can be an invaluable tool for guiding COVID-19 clinical management.Copyright © 2020 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.

39 keywords...

hide…